| Maxygen Initiates Phase IIa Clinical Trial of MAXY-G34 in Breast ...
REDWOOD CITY, Calif., July 2 /PRNewswire-FirstCall/ -- Maxygen, Inc. today announced that it has initiated a phase IIa trial to evaluate the efficacy, safety and tolerability of MAXY-G34 in the treatment of chemotherapy-induced neutropenia. MAXY-G34 is a novel pegylated granulocyte colony stimulating factor (PEG-GCSF) shown in preclinical and Phase I studies to have novel and potentially superior properties compared to the current PEG- GCSF therapy. "Patients and physicians have limited options for treatment of neutropenia," said Russell Howard, chief executive officer of Maxygen. "With MAXY-G34, we hope to expand those options and improve the outcome for many chemotherapy patients. During this first Phase II trial we will begin to learn more about how our drug might play a role in the large, undifferentiated GCSF market." The Phase IIa trial, which will be conducted at multiple centers in Eastern Europe, is the first trial of MAXY-G34 in patients.
Rescue Remedy Is An Effective All-Natural Stress, Anxiety Reliever ...
A just published scientific study conducted by researchers at the University of Miami School of Nursing in conjunction with The Sirkin Creative Living Center (SCLC) has found that Rescue Remedy™, an all-natural remedy created from flower essences, is an effective over-the-counter stress reliever with a comparable effect to traditional pharmaceutical drugs yet without any of the known adverse side effects, including addiction.
Rescue Remedy, manufactured by Nelsons, contains five flower essences: Rock Rose to alleviate terror and panic, Impatiens to mollify irritation and impatience, Clematis to combat inattentiveness, Star of Bethlehem to ease shock, and Cherry Plum to calm irrational thoughts. Available in a convenient spray bottle or in drop form, it helps to provide better emotional balance and fast, convenient relief from everyday stress.
Cytokinetics Announces Data From Phase II Clinical Trial of ...
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the final results from a multicenter Phase II clinical trial sponsored by GlaxoSmithKline (GSK), which evaluated ispinesib in patients with locally advanced or metastatic breast cancer. Ispinesib is a novel small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin essential for proper cell division. Ispinesib has arisen from a broad strategic collaboration between Cytokinetics and GlaxoSmithKline (GSK) to discover, develop and commercialize novel small molecule therapeutics targeting human mitotic kinesins for applications in the treatment of cancer and other diseases. This Phase II clinical trial was designed to evaluate the safety and efficacy of ispinesib in the second- or third-line treatment of patients with locally advanced or metastatic breast cancer whose disease had recurred or progressed despite treatment with anthracyclines and taxanes.
|
